Drugs / E2730
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04676685 | Dec 2020 → Jun 2021 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03451890 | Feb → Sep 2018 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03054194 | Jan → Mar 2017 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03603639 | Jul 2018 → Feb 2019 | photosensitive epilepsy | Eisai Inc. | Terminated | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-30 | Eisai Inc. | EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND E2730 AT THE 75TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING eisai.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E2730 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03451890 ↗ |
| Route | Oral | “single oral dose of E2730” NCT03054194 ↗ |